USANA Health Sciences, Inc. today announced financial results for its fiscal first quarter ended March 29, 2025. Key Financial Results First Quarter 2025 vs. First Quarter 2024 Net sales of $250 ...

SEATTLE, WA / ACCESS Newswire / April 22, 2025 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics ...

Arcturus Therapeutics Holdings Inc.’s ARCT share price has surged by 6.84%, which has investors questioning if this is right ...

In a report released yesterday, Lili (Aurélie) Nsongo from Leerink Partners maintained a Hold rating on Arcturus Therapeutics ( ARCT – Research Report ), with a price target of $63.00. Discover ...

The creative services division of Ross Video, Rocket Surgery, and Arcturus have signed an agreement aimed at promoting ...

Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, for active immunization to ...

In the preceding three months, 5 analysts have released ratings for Nektar Therapeutics NKTR, presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments ...

Analyst Price Forecast Suggests 35.52% Upside As of April 2, 2025, the average one-year price target for Tempest Therapeutics is $9.69/share. The forecasts range from a low of $5.05 to a high of ...

The two brightest nighttime stars available in the Shamokin sky are Sirius and Arcturus. April is the only month of the year ...